Related Experiment Video
Updated: Jun 28, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
Limited utility of rapamycin in severe, refractory Wegener's granulomatosis
Curry L Koening1, José Hernández-Rodríguez, Eamonn S Molloy
1Cleveland Clinic, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland, OH, USA. Curry.Koening@hsc.utah.edu
Objective:
We report our experience using rapamycin in patients with Wegener's granulomatosis (WG) who failed to achieve remission with conventional treatment.
Methods:
Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively.
Results:
Four patients treated with rapamycin sustained remissions of at least 6 months' duration while receiving prednisone
Conclusion:
Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.
More Related Videos
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025